DirectorDealingsBot

Insider buying at Tenax Therapeutics signals confidence in its PH‑HFpEF levosimendan pipeline—explore why executives see long‑term upside despite current losses.

Palaisade Bio insider buy signals confidence in its Phase III Crohn’s drug; watch for FDA filing and market launch in 2026.

Southwest Gas insider sales reveal a planned portfolio shift and possible valuation reassessment—see what the recent 11,000‑share sell‑off means for investors.

Broadwood’s steady buying of STAAR Surgical shares signals confidence in its safe, FDA‑cleared EDOF lenses—backed by strong 88% success rates—and a projected $650 million U.S. cataract implant revenue in 2027–29, making STAAR a top contender for inv…

Atlas Lithium’s CEO sells shares calmly, yet the firm’s Neves lithium project and low costs signal strong long‑term upside for investors.

Spyre Therapeutics’ new executive option grants signal confidence and long‑term commitment to its IBD antibody pipeline, highlighting potential upside and investor interest.

WMC CEO’s Rule 10b‑5‑1 sale of 100k shares at $100.31 sparked a 435 % social‑media surge, yet little market impact—analyzing regulatory safety, coal‑price risks and Alabama expansion prospects.

Arcellx insider trading recap: CMO Heery Christopher’s RSU vesting and tax‑sell moves reveal routine liquidity steps, not speculative bets, while positive sentiment and a 7.6% weekly surge hint at investor confidence in the biotech’s Phase II pipeli…

Insider buy signals confidence in Tenax Therapeutics’ levosimendan‑based pulmonary hypertension drug, highlighting Phase 3 readiness and FDA‑approved IND milestones.

Explore how Dennis Polk’s insider trades reveal TD Synnex’s 5G, supply‑chain, and AI strategy—and uncover practical cyber‑risk controls for IT leaders.